Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mediastinal Grey Zone Lymphoma”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Early research (Phase 1)Study completedNCT02568553
What this trial is testing

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+23 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT03610724
What this trial is testing

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Who this might be right for
Non-Hodgkin Lymphoma
Novartis Pharmaceuticals 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT05507541
What this trial is testing

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+25 more
Mayo Clinic 10
Testing effectiveness (Phase 2)Looking for participantsNCT07283822
What this trial is testing

Amping up With PemJAK

Who this might be right for
Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more
Seda S. Tolu 53
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Very early researchUnknownNCT05208853
What this trial is testing

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Who this might be right for
Hodgkin LymphomaNK/T Cell LymphomaPeripheral T Cell Lymphoma, Unspecified+5 more
Zhejiang University 9
Not applicableStudy completedNCT03037177
What this trial is testing

Mediastinal Grey Zone Lymphoma From the LYSA

Who this might be right for
Mediastinal Grey Zone Lymphoma
Hospices Civils de Lyon 99
Early research (Phase 1)Looking for participantsNCT04231877
What this trial is testing

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
University of Washington 56
Testing effectiveness (Phase 2)Study completedNCT00001337
What this trial is testing

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI) 348
Testing effectiveness (Phase 2)Study completedNCT01994850
What this trial is testing

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

Who this might be right for
CD30 Positive Primary Mediastinal Large B-cell LymphomaCD30-Positive Diffuse Large B-Cell LymphomaCD30-Positive Gray Zone Lymphoma
Abramson Cancer Center at Penn Medicine 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54